P/E at 35.47 vs Industry's 37.61: What the Data Shows for Sun Pharmaceutical Industries Ltd

1 hour ago

Share Via

A price-to-earnings ratio of 35.47 against an industry average of 37.61 reveals a modest valuation discount for Sun Pharmaceutical Industries Ltd. Previously rated Buy by MarketsMojo, the stock’s rating was reassessed on 3 September 2026. While the one-year return of 13.49% comfortably outpaces the Sensex’s decline of 8.79%, the short-term momentum shows a more nuanced picture with a slight dip over the past month. The data presents a compelling dual narrative depending on the timeframe under consideration.

Valuation Picture: A Slight Discount in a High-P/E Sector

Sun Pharmaceutical Industries Ltd trades at a P/E of 35.47, which is approximately 5.7% below the Pharmaceuticals & Biotechnology industry average of 37.61. This discount suggests that the market is pricing the stock with a degree of caution relative to its peers, despite its large-cap stature and established market presence. The sector itself commands elevated valuations, reflecting growth expectations and defensive qualities amid broader market volatility. The stock’s valuation discount may imply concerns over near-term earnings growth or competitive pressures, but it also offers a relative value proposition within a premium sector. Previously rated Hold, what is Sun Pharmaceutical Industries Ltd’s current rating?

Performance Across Timeframes: Divergent Momentum

Examining returns across multiple horizons reveals a complex performance profile. Over the past year, Sun Pharmaceutical Industries Ltd has delivered a robust 13.49% gain, significantly outperforming the Sensex’s 8.79% loss during the same period. This outperformance extends to longer horizons, with three-year and five-year returns of 64.87% and 142.38% respectively, dwarfing the Sensex’s 13.53% and 27.18% gains. However, the short-term picture is less encouraging: the stock declined 1.85% over the past month, slightly underperforming the Sensex’s 3.35% fall, and has barely moved over the last three months with a marginal 0.12% gain compared to the Sensex’s 2.79% decline. This suggests a recent loss of momentum despite the strong medium-term trend — is this a temporary pause or a sign of deeper weakness?

Moving Average Configuration: Mixed Technical Signals

The technical setup for Sun Pharmaceutical Industries Ltd is characterised by a nuanced moving average configuration. The stock is currently trading above its 5-day and 200-day moving averages, signalling short-term resilience and long-term support. However, it remains below the 20-day, 50-day, and 100-day moving averages, indicating that the intermediate trend is still under pressure. This pattern often reflects a recent bounce within a broader downtrend or consolidation phase. The stock’s two-day consecutive gain of 1.88% adds to the short-term positive momentum, but the failure to break above the mid-term moving averages suggests that the recovery may be tentative. The 200-day average acting as a floor is a key technical level to watch — is this a genuine recovery or a dead-cat bounce?

Sector Context: Mixed Results Amidst Pharmaceutical Volatility

The Pharmaceuticals & Biotechnology sector has seen a mixed bag of results recently. Out of 28 stocks that have declared results, 13 reported positive outcomes, 11 were flat, and 4 posted negative results. This distribution highlights the sector’s uneven recovery and the challenges faced by companies in maintaining growth momentum. How does Sun Pharmaceutical Industries Ltd’s performance stack up against its sector peers? The stock’s relative valuation discount and solid medium-term returns suggest it remains a significant player, but the sector’s patchy results may be contributing to the cautious sentiment reflected in the stock’s recent price action.

Rating Context: Previously Rated Buy, Now Reassessed

Sun Pharmaceutical Industries Ltd was previously rated Buy by MarketsMOJO before its rating was updated on 3 September 2026. The reassessment reflects a comprehensive four-parameter analysis incorporating valuation, performance, technicals, and sector context. While the stock’s valuation discount relative to the industry and its strong one-year and longer-term returns support a positive view, the recent short-term underperformance and mixed technical signals have introduced caution. Should investors in Sun Pharmaceutical Industries Ltd hold, buy more, or reconsider?

Conclusion: A Stock Balancing Valuation, Performance, and Technical Signals

The data for Sun Pharmaceutical Industries Ltd paints a picture of a large-cap pharmaceutical stock trading at a slight valuation discount within a premium sector. Its strong one-year and longer-term returns contrast with recent short-term underperformance and a mixed moving average configuration, suggesting a stock in a phase of consolidation or tentative recovery. The sector’s mixed results add further complexity to the outlook. The rating update from a previous Buy reflects these nuanced factors, balancing the stock’s strengths against emerging caution. What is the current rating for Sun Pharmaceutical Industries Ltd, and how should investors interpret this data?

Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year Start at 33% Off →

{{stockdata.stock.stock_name.value}} Live

{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)

{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)

MOJO SCORE